{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001653087","name":"Alector, Inc.","summary":"Alector, Inc. is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Lewy body dementia. Its pipeline includes nivisnebart, a progranulin-elevating antibody in Phase 2 for early AD co-developed with GSK, plus preclinical programs AL137 (anti-amyloid beta), AL050 (GCase enzyme replacement), and ABC-enabled siRNA candidates targeting tau, alpha-synuclein, and NLRP3, all leveraging its proprietary Alector Brain Carrier (ABC) blood-brain barrier delivery platform.","people":[],"products":[{"name":"Nivisnebart (AL101/GSK4527226)","type":"platform","description":"Investigational anti-PGRN monoclonal antibody designed to elevate progranulin levels for treatment of early Alzheimer's disease and potentially Parkinson's disease."},{"name":"AL137","type":"platform","description":"Proprietary anti-amyloid beta antibody paired with ABC platform in preclinical development for Alzheimer's disease treatment."},{"name":"AL050","type":"platform","description":"GCase enzyme replacement therapy paired with ABC platform in preclinical development for Parkinson's disease and Lewy body dementia."},{"name":"AL064","type":"platform","description":"Lead ABC-enabled tau siRNA program for Alzheimer's disease and other tauopathies, advancing to IND-enabling studies."},{"name":"ADP062-ABC","type":"platform","description":"Alpha-synuclein siRNA program for Parkinson's disease using the ABC platform, in early-stage development."},{"name":"ADP065-ABC","type":"platform","description":"NLRP3 siRNA program for multiple neurodegenerative conditions using the ABC platform, in early-stage development."},{"name":"Alector Brain Carrier (ABC)","type":"platform","description":"Proprietary blood-brain barrier delivery platform designed to transport antibodies, enzymes, and siRNA therapeutics across the BBB via transferrin receptor targeting."}],"partnerships":[{"partner_name":"GlaxoSmithKline (GSK) / Glaxo Wellcome UK Limited","partnership_type":"development","description":"July 2021 Collaboration and License Agreement for co-development of nivisnebart in early Alzheimer's disease; Alector funds up to $140.5 million in shared development costs for Phase 2 trial.","start_date":null}],"affiliations":[],"origin":{"leaf":"9249de5c1b3ed9cd12eb33b510dbbe0da794ce5c0d3e84d5c3b85aad18995a4b","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"4f520512d64e2428cab222bcdef15b545bc54deb0cdf75ecdd9b9b4ec195c886","parent":"79eab51362ea1191a26a52136029a92db5b26af7cc36350263045526d0795d64","source":"0001193125-26-071593","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}